Research Article
BibTex RIS Cite
Year 2014, Volume: 31 Issue: 1, 31 - 36, 05.06.2014

Abstract

References

  • Bloomgren, G., Richman, S., Hotermans, C., Subramanyam, M., Goelz, S., Natarajan, A., Lee, S., Plavina, T., Scanlon, J.V., Pharm, D., Sandrock, A., Bozic, C., 2012. Risk of natalizumab associated progressive multifocal leukoencephalopathy. N. Engl. J. Med. 366, 1870-1880. doi: 1056/NEJMoa1107829.
  • Bozic, C., Richman, S., Plavina, T., Natarajan, A., Scanlon, J.V., Subramanyam, M., Sandrock, A., Bloomgren, G., 2011. Anti-John Cunningham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann. Neurol. 70, 742-750. doi: 10.1002/ana.22606. Bozic, C., Richman, S., Plavina, T., Natarajan, A., Scanlon, J., Subramanyam, M., Sandrock, A. and Bloomgren, G., 2012. Anti-JCV antibody prevalence in patients with relapsing multiple sclerosis receiving or considering treatment with natalizumab: baseline results of STRATIFY- Neurology. 78, S41.002.
  • Bozic, C., Subramanyam, M., Paes, D., Richman, S., Plavina, T., Zhang, A., Ticho, B., 2012. Anti-JC virus antibody prevalence in the JCV Epidemiology in MS trial. ECTRIMS, October 10-13, Lyon, France.
  • Fig. Prevalence of anti-JCV antibodies is higher in the patients who have used immunosuppressant treatments (p<0.05). Fig. Prevalence between the patients exposed to natalizumab (p=0.155).

Anti-John Cunningham Virus antibody prevalence in multiple sclerosis patients in Turkey

Year 2014, Volume: 31 Issue: 1, 31 - 36, 05.06.2014

Abstract

Exposure to John Cunningham Virus (JCV) has been associated with Progressive Multifocal Leukoencephalopathy (PML) in Multiple Sclerosis (MS) patients under specific treatments. In order to assess the identifiable risks of Turkish relapsing-remitting multiple sclerosis (RRMS) patients, the seroprevalence rate of JCV antibodies was investigated and compared with demographic and therapy related factors. Serum samples were collected from 308 RRMS patients at 24 centers, and tested by STRATIFY JCV assay for the presence of anti-JCV antibodies. Also, demographic, disease and treatment data were collected at the same time and were used for analysis of associations with seropositivity. The prevalence of anti-JCV antibodies was observed to be 68.2%, which is higher than most countries. There was a trend in terms of higher seroprevalence of antibodies in older patients, and male patients. There was no association with previous
natalizumab use, but there was a significantly higher seroprevalence in patients who used immunosuppressant therapies (p<0.05). JCV prevalence rate is observed to be
high in Turkish MS patients, therefore it would be beneficial to use this marker as a risk stratification tool in clinical decision making.

References

  • Bloomgren, G., Richman, S., Hotermans, C., Subramanyam, M., Goelz, S., Natarajan, A., Lee, S., Plavina, T., Scanlon, J.V., Pharm, D., Sandrock, A., Bozic, C., 2012. Risk of natalizumab associated progressive multifocal leukoencephalopathy. N. Engl. J. Med. 366, 1870-1880. doi: 1056/NEJMoa1107829.
  • Bozic, C., Richman, S., Plavina, T., Natarajan, A., Scanlon, J.V., Subramanyam, M., Sandrock, A., Bloomgren, G., 2011. Anti-John Cunningham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann. Neurol. 70, 742-750. doi: 10.1002/ana.22606. Bozic, C., Richman, S., Plavina, T., Natarajan, A., Scanlon, J., Subramanyam, M., Sandrock, A. and Bloomgren, G., 2012. Anti-JCV antibody prevalence in patients with relapsing multiple sclerosis receiving or considering treatment with natalizumab: baseline results of STRATIFY- Neurology. 78, S41.002.
  • Bozic, C., Subramanyam, M., Paes, D., Richman, S., Plavina, T., Zhang, A., Ticho, B., 2012. Anti-JC virus antibody prevalence in the JCV Epidemiology in MS trial. ECTRIMS, October 10-13, Lyon, France.
  • Fig. Prevalence of anti-JCV antibodies is higher in the patients who have used immunosuppressant treatments (p<0.05). Fig. Prevalence between the patients exposed to natalizumab (p=0.155).
There are 4 citations in total.

Details

Primary Language English
Subjects Health Care Administration
Journal Section Basic Medical Sciences
Authors

Mefkure Eraksoy This is me

Kadriye Agan This is me

Fikri Ak This is me

Omer Anlar This is me

Belgin Balcı This is me

Cavit Boz This is me

Yahya Celık This is me

Seref Demırkaya This is me

Husnu Efendı This is me

Muhtesem Gecızlıoglu This is me

Dilek Gunal This is me

Hulya Aydın Gungor This is me

Nihal Isık This is me

Egemen Idılman This is me

Rana Karabudak This is me

Aslı Kurne This is me

Munife Neyal This is me

Serkan Ozakbas This is me

Ozgul Ekmekcı Ozbay This is me

Cemal Ozcan This is me

Nese Oztekın This is me

Musa Ozturk This is me

Sabahattin Saıp This is me

Aksel Sıva This is me

Aysun Soysal This is me

Ozlem Taskapılıoglu This is me

Murat Terzı This is me

Omer Turan This is me

Recai Turkoglu This is me

Nezih Yucemen This is me

Ayse Yuceyar This is me

Yasar Zorlu This is me

Cunay Ulku This is me

Huseyin Dıb This is me

Deniz Uren This is me

Publication Date June 5, 2014
Submission Date December 16, 2013
Published in Issue Year 2014 Volume: 31 Issue: 1

Cite

APA Eraksoy, M., Agan, K., Ak, F., Anlar, O., et al. (2014). Anti-John Cunningham Virus antibody prevalence in multiple sclerosis patients in Turkey. Journal of Experimental and Clinical Medicine, 31(1), 31-36.
AMA Eraksoy M, Agan K, Ak F, Anlar O, Balcı B, Boz C, Celık Y, Demırkaya S, Efendı H, Gecızlıoglu M, Gunal D, Aydın Gungor H, Isık N, Idılman E, Karabudak R, Kurne A, Neyal M, Ozakbas S, Ekmekcı Ozbay O, Ozcan C, Oztekın N, Ozturk M, Saıp S, Sıva A, Soysal A, Taskapılıoglu O, Terzı M, Turan O, Turkoglu R, Yucemen N, Yuceyar A, Zorlu Y, Ulku C, Dıb H, Uren D. Anti-John Cunningham Virus antibody prevalence in multiple sclerosis patients in Turkey. J. Exp. Clin. Med. June 2014;31(1):31-36.
Chicago Eraksoy, Mefkure, Kadriye Agan, Fikri Ak, Omer Anlar, Belgin Balcı, Cavit Boz, Yahya Celık, Seref Demırkaya, Husnu Efendı, Muhtesem Gecızlıoglu, Dilek Gunal, Hulya Aydın Gungor, Nihal Isık, Egemen Idılman, Rana Karabudak, Aslı Kurne, Munife Neyal, Serkan Ozakbas, Ozgul Ekmekcı Ozbay, Cemal Ozcan, Nese Oztekın, Musa Ozturk, Sabahattin Saıp, Aksel Sıva, Aysun Soysal, Ozlem Taskapılıoglu, Murat Terzı, Omer Turan, Recai Turkoglu, Nezih Yucemen, Ayse Yuceyar, Yasar Zorlu, Cunay Ulku, Huseyin Dıb, and Deniz Uren. “Anti-John Cunningham Virus Antibody Prevalence in Multiple Sclerosis Patients in Turkey”. Journal of Experimental and Clinical Medicine 31, no. 1 (June 2014): 31-36.
EndNote Eraksoy M, Agan K, Ak F, Anlar O, Balcı B, Boz C, Celık Y, Demırkaya S, Efendı H, Gecızlıoglu M, Gunal D, Aydın Gungor H, Isık N, Idılman E, Karabudak R, Kurne A, Neyal M, Ozakbas S, Ekmekcı Ozbay O, Ozcan C, Oztekın N, Ozturk M, Saıp S, Sıva A, Soysal A, Taskapılıoglu O, Terzı M, Turan O, Turkoglu R, Yucemen N, Yuceyar A, Zorlu Y, Ulku C, Dıb H, Uren D (June 1, 2014) Anti-John Cunningham Virus antibody prevalence in multiple sclerosis patients in Turkey. Journal of Experimental and Clinical Medicine 31 1 31–36.
IEEE M. Eraksoy, “Anti-John Cunningham Virus antibody prevalence in multiple sclerosis patients in Turkey”, J. Exp. Clin. Med., vol. 31, no. 1, pp. 31–36, 2014.
ISNAD Eraksoy, Mefkure et al. “Anti-John Cunningham Virus Antibody Prevalence in Multiple Sclerosis Patients in Turkey”. Journal of Experimental and Clinical Medicine 31/1 (June 2014), 31-36.
JAMA Eraksoy M, Agan K, Ak F, Anlar O, Balcı B, Boz C, Celık Y, Demırkaya S, Efendı H, Gecızlıoglu M, Gunal D, Aydın Gungor H, Isık N, Idılman E, Karabudak R, Kurne A, Neyal M, Ozakbas S, Ekmekcı Ozbay O, Ozcan C, Oztekın N, Ozturk M, Saıp S, Sıva A, Soysal A, Taskapılıoglu O, Terzı M, Turan O, Turkoglu R, Yucemen N, Yuceyar A, Zorlu Y, Ulku C, Dıb H, Uren D. Anti-John Cunningham Virus antibody prevalence in multiple sclerosis patients in Turkey. J. Exp. Clin. Med. 2014;31:31–36.
MLA Eraksoy, Mefkure et al. “Anti-John Cunningham Virus Antibody Prevalence in Multiple Sclerosis Patients in Turkey”. Journal of Experimental and Clinical Medicine, vol. 31, no. 1, 2014, pp. 31-36.
Vancouver Eraksoy M, Agan K, Ak F, Anlar O, Balcı B, Boz C, Celık Y, Demırkaya S, Efendı H, Gecızlıoglu M, Gunal D, Aydın Gungor H, Isık N, Idılman E, Karabudak R, Kurne A, Neyal M, Ozakbas S, Ekmekcı Ozbay O, Ozcan C, Oztekın N, Ozturk M, Saıp S, Sıva A, Soysal A, Taskapılıoglu O, Terzı M, Turan O, Turkoglu R, Yucemen N, Yuceyar A, Zorlu Y, Ulku C, Dıb H, Uren D. Anti-John Cunningham Virus antibody prevalence in multiple sclerosis patients in Turkey. J. Exp. Clin. Med. 2014;31(1):31-6.